
|Articles|December 7, 2020
The Mainstream Patient: December 7
Author(s)Morgan Petronelli
This week’s edition of The Mainstream Patient features stories on probiotic skincare, sallow skin, the differences between melasma and hyperpigmentation, plus more.
Advertisement
In this week’s edition, Allure features stories on the differences between melasma and hyperpigmentation, and dives into what will happen to your skin if you never leave the house. Also, Hello Giggles provides an in-depth guide to probiotic skin and its benefits. Women’s Health explains what sallow skin is and the causes of it. Finally. Shape takes a look at babassu oil for the skin and investigates in silicones are actually bad for your hair.
Advertisement
Related to this article

From “Botox in a bottle” to castor oil and face taping, Dermatology Times reviews the evidence behind 3 viral dermatology trends from October.

Dermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.

The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.

Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.

Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.

Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
The Scariest Skin Care Trends Haunting Patients This Halloween
3
October Social Media Mythbusters: 3 Viral Beauty Claims, Debunked
4
Improving Early Identification and Escalation of HS
5


